Neuropathy is a frequent complication of diabetes mellitus (DM) and is associated with the increased risk ofamputation and vascular events. Tight glycemic control is an important component inthe prevention of diabetic neuropathy. However, accumulating data suggest that angiotensin receptor blockers (ARBs) might also be useful in this setting. We discuss the findings of both experimental and clinical studies that evaluated the effects of ARBs on indices of diabetic neuropathy. We also review the implicated mechanisms of the neuroprotective actions of these agents. Overall, it appears that ARBs might be a helpful tool for preventing and delaying the progression of diabetic neuropathy, but more data are needed to clarify their role in the management of this overlooked complication of DM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410471 | PMC |
| http://dx.doi.org/10.3390/jpm12081253 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Do SGLT2 Inhibitors Protect the Kidneys? An Alternative Explanation.
Endocr Metab Immune Disord Drug Targets
January 2025
Sheba Medical Center, Institute of Endocrinology, Tel-Hashomer, Israel.
SGLT2 inhibitors are a family of drugs that were developed to treat diabetes mellitus. In randomized controlled trials, SGLT2 inhibitors seem to prevent kidney deterioration in patients with nephropathies, both diabetic and non-diabetic. However, in contrast to biochemical/physiological results (proteinuria and serum creatinine levels) that improve in all studies, the clinical results (all-cause mortality, cardiovascular death, need for dialysis, or renal transplant) do not consistently improve.
View Article and Find Full Text PDFFaecal microbiota transplantation for patients with diabetes type 1 and severe gastrointestinal neuropathy (FADIGAS): a randomised, double-blinded, placebo-controlled trial.
EClinicalMedicine
January 2025
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Background: Diabetic gastroenteropathy is associated with nausea, vomiting, bloating, pain, constipation, and diarrhoea. Current therapies are scarce. We tested faecal microbiota transplantation (FMT) for patients with type 1 diabetes and gastroenteropathy.
View Article and Find Full Text PDFDiabetic foot ulcer photography study: a study within a trial to assess the reliability of two-dimensional (2D) photography for the assessment of ulcer healing in patients with diabetes-related foot ulcers-protocol paper.
BMJ Open
January 2025
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Background: The primary endpoint in diabetes-related foot ulcer (DFU) trials is often time to healing, defined as complete re-epithelialisation with absence of drainage, requiring clinical expert assessment as the gold standard. Central blinded photograph review for confirmation of healing is increasingly being undertaken for internal validity. The Diabetic Foot Ulcer Photography study aims to determine the agreement between blinded independent review panel members for assessing ulcer healing status in patients with DFUs.
View Article and Find Full Text PDFCorrelation between serum adenosine deaminase levels and risk of diabetic foot ulcers in patients with type 2 diabetes mellitus.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Orthopedics, Southwest Hospital, Army Medical University, Chongqing 400038, China.
Objectives: Adenosine deaminase (ADA) is a critical enzyme in the catabolism of adenosine acid during purine metabolism and plays a significant role in the diagnosis and monitoring of various diseases. This study aims to investigate the relationship between serum ADA levels and risk of diabetic foot ulcers (DFU) in patients with type 2 diabetes mellitus (T2DM), providing a clinical basis for the prevention and treatment of DFU.
Methods: A retrospective study was conducted on 2 719 T2DM patients diagnosed at the Southwest Hospital of Army Medical University from January 2019 to January 2020.
ASPIRIN-TRIGGERED LIPOXIN A4 REDUCES NEUROPATHIC PAIN AND ANXIETY-LIKE BEHAVIOURS IN MALE DIABETIC RATS: ANTINOCICEPTIVE ENHANCEMENT BY CANNABINOID RECEPTOR AGONISTS.
Eur J Pharmacol
January 2025
Laboratory of Pharmacology of Pain, Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil.
Neuropathy is the most common complication of diabetes, leading to painful symptoms like hyperalgesia. Current treatments for diabetic painful neuropathy often prove inadequate, necessitating the exploration of new pharmacological approaches. Therefore, this study aimed to investigate the potential antinociceptive effect of aspirin-triggered lipoxin A4 (ATL), a specialized pro-resolving lipid mediator, when administered alone or in combination with cannabinoid agonists, to alleviate diabetic neuropathic pain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!